Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:LLY NYSE:NVO NASDAQ:RYTM NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.90-1.0%$3.17$2.56▼$7.73$569.81M0.184.26 million shs1.99 million shsLLYEli Lilly and Company$1,066.59+2.4%$942.87$623.78▼$1,133.95$980.96B0.483.50 million shs3.47 million shsNVONovo Nordisk A/S$44.91+1.2%$40.29$35.12▼$81.44$198.20B0.7717.38 million shs10.77 million shsRYTMRhythm Pharmaceuticals$87.84-2.6%$87.27$58.71▼$122.20$6.02B1.94778,742 shs479,070 shsVKTXViking Therapeutics$30.89+0.7%$32.95$22.96▼$43.15$3.59B0.722.30 million shs1.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.02%+1.75%-16.43%-33.79%-48.12%LLYEli Lilly and Company+2.37%+6.11%+15.81%+5.76%+47.26%NVONovo Nordisk A/S+1.19%+0.45%+14.60%-5.32%-34.14%RYTMRhythm Pharmaceuticals-2.61%-2.96%+3.12%-11.97%+40.75%VKTXViking Therapeutics+0.68%+2.05%-9.81%-0.45%+13.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.90-1.0%$3.17$2.56▼$7.73$569.81M0.184.26 million shs1.99 million shsLLYEli Lilly and Company$1,066.59+2.4%$942.87$623.78▼$1,133.95$980.96B0.483.50 million shs3.47 million shsNVONovo Nordisk A/S$44.91+1.2%$40.29$35.12▼$81.44$198.20B0.7717.38 million shs10.77 million shsRYTMRhythm Pharmaceuticals$87.84-2.6%$87.27$58.71▼$122.20$6.02B1.94778,742 shs479,070 shsVKTXViking Therapeutics$30.89+0.7%$32.95$22.96▼$43.15$3.59B0.722.30 million shs1.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.02%+1.75%-16.43%-33.79%-48.12%LLYEli Lilly and Company+2.37%+6.11%+15.81%+5.76%+47.26%NVONovo Nordisk A/S+1.19%+0.45%+14.60%-5.32%-34.14%RYTMRhythm Pharmaceuticals-2.61%-2.96%+3.12%-11.97%+40.75%VKTXViking Therapeutics+0.68%+2.05%-9.81%-0.45%+13.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67474.71% UpsideLLYEli Lilly and Company 2.87Moderate Buy$1,220.3714.42% UpsideNVONovo Nordisk A/S 2.13Hold$65.5645.99% UpsideRYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.8150.06% UpsideVKTXViking Therapeutics 2.85Moderate Buy$95.50209.16% UpsideCurrent Analyst Ratings BreakdownLatest VKTX, RYTM, LLY, NVO, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026LLYEli Lilly and Company The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,283.005/21/2026LLYEli Lilly and Company Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$1,350.005/21/2026LLYEli Lilly and Company Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/21/2026LLYEli Lilly and Company Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$1,300.00 ➝ $1,330.005/19/2026LLYEli Lilly and Company Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.005/12/2026NVONovo Nordisk A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/7/2026LLYEli Lilly and Company Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target$880.00 ➝ $900.005/6/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$136.00 ➝ $137.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K14,099.08N/AN/A$1.46 per share1.99LLYEli Lilly and Company$65.18B15.41$25.74 per share41.44$33.13 per share32.19NVONovo Nordisk A/S$46.80B4.28$4.74 per share9.47$7.12 per share6.31RYTMRhythm Pharmaceuticals$189.76M31.72N/AN/A$1.79 per share49.07VKTXViking TherapeuticsN/AN/AN/AN/A$4.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)LLYEli Lilly and Company$20.64B$28.1537.8924.111.1334.98%105.77%23.76%8/5/2026 (Estimated)NVONovo Nordisk A/S$15.51B$4.2610.5413.053.9637.23%63.31%22.19%8/5/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest VKTX, RYTM, LLY, NVO, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million4/30/2026Q1 2026LLYEli Lilly and Company$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion4/29/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/31/2026Q1 2026NVONovo Nordisk A/SN/A$1.0270N/A$1.69N/A$10.85 billion3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 million2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ALLYEli Lilly and Company$6.920.65%+15.18%24.58%11 YearsNVONovo Nordisk A/S$1.753.90%+21.74%41.08%N/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ALatest VKTX, RYTM, LLY, NVO, and ALT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/4/2026LLYEli Lilly and Companyquarterly$1.730.69%5/15/20265/15/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56LLYEli Lilly and Company1.261.501.10NVONovo Nordisk A/S0.590.790.56RYTMRhythm PharmaceuticalsN/A4.173.89VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%LLYEli Lilly and Company82.53%NVONovo Nordisk A/S11.54%RYTMRhythm PharmaceuticalsN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%LLYEli Lilly and Company0.14%NVONovo Nordisk A/S0.07%RYTMRhythm Pharmaceuticals5.90%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million128.02 millionOptionableLLYEli Lilly and Company50,000941.74 million940.42 millionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableVKTX, RYTM, LLY, NVO, and ALT HeadlinesRecent News About These Companies2 Stocks That Could Realistically Double by 2030May 22 at 9:46 AM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 22 at 2:28 AM | americanbankingnews.comCan Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?May 21 at 12:36 PM | zacks.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21 at 8:23 AM | finance.yahoo.comViking Therapeutics to Participate at Upcoming Investor ConferencesMay 21 at 7:05 AM | prnewswire.comBest Weight Loss Drug Stocks to Buy in 2026May 20 at 11:15 PM | fool.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyMay 18, 2026 | fool.comThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comThe Bull Case For Viking Therapeutics (VKTX) Could Change Following New Oral VK2735 Obesity Data ReleaseMay 17, 2026 | finance.yahoo.comThis Hot Weight-Loss Drug Stock May Be a Surprise ChallengerMay 15, 2026 | barchart.comCan Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?May 14, 2026 | zacks.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comLilly Bets on Next-Generation Obesity Drugs to Stay AheadMay 13, 2026 | zacks.comViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026May 12, 2026 | prnewswire.comLGND: 1Q:26 Results Highlight Breadth of PortfolioMay 11, 2026 | finance.yahoo.com75,475 Shares in Viking Therapeutics, Inc. $VKTX Bought by Channel Wealth LLCMay 9, 2026 | marketbeat.comVKTX stock slips overnight: Investors pin hopes on fresh weight-loss data as Pfizer joins Eli Lilly, Novo in GLP-1 warMay 6, 2026 | msn.comViking Therapeutics: Market Betting On Big Upside Through 2030May 5, 2026 | seekingalpha.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | finance.yahoo.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | prnewswire.comHere's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 MonthsMay 4, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026Industrial Chips Are in Rally Mode—5 Ways to PlayBy Thomas Hughes | April 27, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Amazon’s Earnings Just Sent the Stock to New Highs—What’s Next?By Sam Quirke | April 30, 2026VKTX, RYTM, LLY, NVO, and ALT Company DescriptionsAltimmune NASDAQ:ALT$2.90 -0.03 (-1.02%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.90 +0.00 (+0.17%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Eli Lilly and Company NYSE:LLY$1,066.59 +24.94 (+2.39%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$1,065.00 -1.59 (-0.15%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.Novo Nordisk A/S NYSE:NVO$44.91 +0.52 (+1.17%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$44.90 -0.01 (-0.03%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Rhythm Pharmaceuticals NASDAQ:RYTM$87.84 -2.35 (-2.61%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$86.42 -1.43 (-1.62%) As of 05/22/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$30.89 +0.21 (+0.68%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$30.83 -0.06 (-0.19%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
